SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 3,575 Shares

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 3,575 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the transaction, the director directly owned 16,057 shares in the company, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Performance

SIBN opened at $14.97 on Tuesday. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89. The stock has a market cap of $663.92 million, a price-to-earnings ratio of -38.38 and a beta of 0.70. The business has a 50 day moving average of $13.72 and a 200-day moving average of $15.91. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The business had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. On average, equities research analysts expect that SiBone will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

SIBN has been the topic of several research analyst reports. Truist Financial reissued a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, TD Cowen lowered their price target on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

Institutional Trading of SiBone

Several hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of SiBone in the first quarter valued at approximately $225,000. Goldman Sachs Group Inc. raised its position in shares of SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after buying an additional 83,919 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of SiBone in the first quarter valued at approximately $1,818,000. Finally, Legal & General Group Plc boosted its stake in shares of SiBone by 16.1% in the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock valued at $798,000 after buying an additional 5,888 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.